These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36680436)

  • 21. High Drug Resistance Levels Compromise the Control of HIV Infection in Pediatric and Adult Populations in Bata, Equatorial Guinea.
    Rodríguez-Galet A; Ventosa-Cubillo J; Bendomo V; Eyene M; Mikue-Owono T; Nzang J; Ncogo P; Gonzalez-Alba JM; Benito A; Holguín Á
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
    Segujja F; Omooja J; Lunkuse S; Nanyonjo M; Nabirye SE; Nassolo F; Bugembe DL; Bbosa N; Kateete DP; Ssenyonga W; Mayanja Y; Nsubuga RN; Seeley J; Kaleebu P; Ssemwanga D
    AIDS Res Hum Retroviruses; 2020 Sep; 36(9):782-791. PubMed ID: 32475121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients.
    Marjani A; Bokharaei-Salim F; Jahanbakhshi F; Monavari SH; Esghaei M; Kalantari S; Kiani SJ; Ataei-Pirkooh A; Fakhim A; Keyvani H
    Arch Virol; 2020 Jan; 165(1):115-125. PubMed ID: 31741096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.
    Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V
    Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings.
    Manyana S; Pillay M; Gounder L; Khan A; Moodley P; Naidoo K; Chimukangara B
    AIDS Res Ther; 2023 Feb; 20(1):9. PubMed ID: 36759801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings.
    Zhang G; DeVos J; Medina-Moreno S; Wagar N; Diallo K; Beard RS; Zheng DP; Mwachari C; Riwa C; Jullu B; Wangari NE; Kibona MS; Ng'Ang'A LW; Raizes E; Yang C
    PLoS One; 2018; 13(9):e0203296. PubMed ID: 30192818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
    Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338
    [No Abstract]   [Full Text] [Related]  

  • 30. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.
    Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
    Casadellà M; Santos JR; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; Pasquau J; Vivancos MJ; Imaz A; Carmona-Oyaga P; Muñoz-Medina L; Villar-García J; Barrufet P; Paredes R;
    J Antimicrob Chemother; 2020 Dec; 75(12):3517-3524. PubMed ID: 32929472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden.
    Andersson E; Ambikan A; Brännström J; Aralaguppe SG; Yilmaz A; Albert J; Neogi U; Sönnerborg A
    AIDS; 2021 Feb; 35(2):227-234. PubMed ID: 33394670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary resistance to integrase inhibitors in Shenzhen.
    Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
    J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
    Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD
    Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
    Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
    J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.